TIGIT+ CD8+ T cells from patients with AML, GC, or multiple myeloma showed reduced cytokine production, high susceptibility to apoptosis, and significantly reduced proliferation and killing ability. This evidence concerns the gene CD8A and acute myeloid leukemia.